Elanco Animal Health Incorporated (NYSE:ELAN) Position Lessened by Country Club Bank

Country Club Bank decreased its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 1.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 132,073 shares of the company’s stock after selling 2,364 shares during the period. Country Club Bank’s holdings in Elanco Animal Health were worth $1,561,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. ORG Wealth Partners LLC acquired a new stake in shares of Elanco Animal Health during the 3rd quarter valued at about $29,000. AM Squared Ltd bought a new position in Elanco Animal Health during the third quarter valued at approximately $34,000. Wilmington Savings Fund Society FSB acquired a new stake in Elanco Animal Health in the third quarter valued at approximately $35,000. Farther Finance Advisors LLC grew its position in Elanco Animal Health by 158.7% in the third quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock worth $49,000 after acquiring an additional 2,044 shares in the last quarter. Finally, Venturi Wealth Management LLC increased its stake in shares of Elanco Animal Health by 89.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock worth $50,000 after purchasing an additional 1,601 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on ELAN shares. UBS Group initiated coverage on shares of Elanco Animal Health in a research note on Monday, December 9th. They issued a “buy” rating and a $18.00 price objective for the company. Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Barclays increased their price objective on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 8th. Leerink Partners initiated coverage on Elanco Animal Health in a report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 target price for the company. Finally, Morgan Stanley lowered their price target on Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 29th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $16.29.

Elanco Animal Health Price Performance

Shares of NYSE:ELAN opened at $12.03 on Thursday. The company has a market cap of $5.94 billion, a price-to-earnings ratio of 30.06, a PEG ratio of 2.71 and a beta of 1.42. The business has a 50 day moving average price of $12.10 and a 200 day moving average price of $13.22. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. Elanco Animal Health Incorporated has a twelve month low of $11.11 and a twelve month high of $18.80.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.04 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company’s quarterly revenue was down 3.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.18 earnings per share. Research analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.